Ovarian Cancer Prevention

Key points
- As parity is inversely related to the risk of ovarian cancer, having at least one child is protective of the disease with a risk reduction of 0.3to 0.4.
- Fenretinide (4-hydroxyphenyl-all-trans-retinoic acid amide), a vitamin A derivative, has been given to women with unilateral breast cancer in an effort to reduce the risk of contralateral breast cancer.
- The performance of a prophylactic oophorectomy will reduce, but not eliminate, the excess risk of cancer in women at high risk for developing ovarian cancer.
- Remarkably, use of oral contraceptives for 5 or more years reduces their relative risk to 0.5, ie (there is a 50% reduction in the likelihood of developing ovarian cancer).
As parity is inversely related to the risk of ovarian cancer, having at least one child is protective of the disease with a risk reduction of 0.3to 0.4. Remarkably, use of oral contraceptives for 5 or more years reduces their relative risk to 0.5, ie (there is a 50% reduction in the likelihood of developing ovarian cancer). Women who have had two children and have used oral contraceptives for 5 or more years have a relative risk of ovarian cancer as low as 0.3, or a 70% reduction. Therefore, the oral contraceptive pill is the only documented method of chemoprevention for ovarian cancer, and it should be recommended to women for this purpose. When counseling patients regarding birth control options, this important benefit of oral contraceptive use should be emphasized. This is also important for women with a strong family history of ovarian cancer.
Fenretinide
Fenretinide (4-hydroxyphenyl-all-trans-retinoic acid amide), a vitamin A derivative, has been given to women with unilateral breast cancer in an effort to reduce the risk of contralateral breast cancer. In a prospective, randomized, placebo-controlled trial conducted in Italy, women with unilateral breast cancer were given either oral fenretinide or a placebo for five years. In the treatment group, no ovarian cancers developed during the five years on study, whereas there were 6 cases of ovarian cancer in the control group (p < .01). When participants were followed long-term, however, the protective effect disappeared after discontinuing the drug. In cell culture, fenretinide can induce apoptosis in ovarian cancer cells and in normal ovarian surface epithelial cells. Trials are planned in the United States to determine the effect of fenretinide on the ovaries of women at high risk for developing ovarian cancer who will receive the drug prior to prophylactic oophorectomy.
Oophorectomy
The performance of a prophylactic oophorectomy will reduce, but not eliminate, the excess risk of cancer in women at high risk for developing ovarian cancer. Because the entire peritoneum is at risk, peritoneal carcinomas can occur even after prophylactic oophorectomy in less than 5% of cases. Because the ovaries provide protection from cardiovascular disease and osteoporosis, prophylactic oophorectomy should not be routinely performed in premenopausal women at average risk for ovarian cancer.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsResearchers at Case Comprehensive Cancer Center discover ovarian cancer biomarker
Researchers at Case Western Reserve University have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer – a breakthrough that has the potential…
9 January 2014
NewsResearch backs risk-reduction surgery for ovarian cancer
A study by Manchester scientists backs preventative surgery to improve survival for women who are at greater risk of getting ovarian cancer and suggests it appears helpful for women at risk of getting breast cancer…
18 December 2013
NewsSurviving Ovarian Cancer: Rutgers Scientists Attack Drug Resistant Cancer Cells
Scientists at Rutgers University have developed a targeted drug delivery system that they believe could make ovarian cancer more treatable and increase survival rates for the most deadly gynecological cancer in the…



